Can a drug boost blood cells and delay cancer in people with CCUS?

NCT ID NCT06788691

First seen Mar 25, 2026 · Last updated May 16, 2026 · Updated 8 times

Summary

This study tests the drug luspatercept in 50 adults with clonal cytopenias of uncertain significance (CCUS), a condition where blood cell counts are low and there is a risk of developing blood cancer. Participants receive injections every three weeks for up to 48 weeks. The goal is to see if the drug can improve red blood cell, platelet, or white blood cell counts and delay progression to more serious diseases like myelodysplastic syndromes or leukemia.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Weill Cornell Medical College

    RECRUITING

    New York, New York, 10021, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.